title: Diagnosing metabolic syndrome in type 2 diabetic Turkish patients: comparison of AHA/NHLBI and IDF definitions.
abstract: OBJECTIVE
  The objective of this study was to determine the percentage of metabolic syndrome (MetS) in a Turkish population with type 2 diabetes mellitus (T2DM) according to the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) and International Diabetes Federation (IDF) definitions and to assess the agreement among these definitions.
  
  
  BACKGROUND
  It is essential to identify the prevalence of MetS in diabetic patients, as MetS is a stronger risk factor for cardiovascular disease in patients with T2DM than in non-diabetic subjects.
  
  
  METHODS
  235 consecutive patients with T2DM were included in the study. The MetS was defined according to AHA/NHLBI and IDF definitions. Cohen's kappa was used as a measure of agreement between the two definitions. Logistic regression analysis was performed to calculate the odds ratios.
  
  
  RESULTS
  The percentage of MetS was 85.1% by AHA/NHLBI and 87.2% by IDF criteria. The agreement between AHA/NHLBI and IDF was fairly good (kappa = 0.55). Females were more affected than males. When the frequencies of each individual feature of the MetS according the definitions were assessed, hypertension was the most common feature in males, whilst abdominal obesity was in females. Serum triglyceride and waist circumference had the highest predictive ability for MetS according to AHA/NHLBI and IDF definitions, respectively.
  
  
  CONCLUSIONS
  The MetS is a common condition among diabetic patients. Since diabetic patients carry a cluster of cardiovascular risk factors, correct identification of the MetS among this population is of great importance, for an integrated approach to reduce the high costs and the associated disabilities (Tab. 5, Fig. 2, Ref. 54).
authors.affiliation: Ege University Faculty of Medicine, Department of Clinical Biochemistry, 35100 Izmir, Turkey. gunes.basol@ege.edu.tr
authors.forename: G
authors.initials: G
authors.lastname: Basol
authors.forename: B
authors.initials: B
authors.lastname: Barutcuoglu
authors.forename: Y
authors.initials: Y
authors.lastname: Cakir
authors.forename: B
authors.initials: B
authors.lastname: Ozmen
authors.forename: Z
authors.initials: Z
authors.lastname: Parildar
authors.forename: T
authors.initials: T
authors.lastname: Kose
authors.forename: D
authors.initials: D
authors.lastname: Ozmen
authors.forename: O
authors.initials: O
authors.lastname: Bayindir
mesh_terms: D000572:American Heart Association; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000175:diagnosis*; D008875:Middle Aged; D054555:National Heart, Lung, and Blood Institute (U.S.); D012955:Societies, Medical; D014481:United States